Insider Transactions in Q4 2024 at Akero Therapeutics, Inc. (AKRO)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 15
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
9,061
-5.47%
|
$253,708
$28.26 P/Share
|
|
Nov 15
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,061
+9.82%
|
$190,281
$21.1 P/Share
|
|
Nov 06
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-11.88%
|
$350,000
$35.19 P/Share
|
|
Nov 06
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+10.62%
|
$0
$0.62 P/Share
|
|
Nov 01
2024
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
108,366
-8.06%
|
$3,359,346
$31.99 P/Share
|
|
Nov 01
2024
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
108,366
+7.35%
|
$2,275,686
$21.1 P/Share
|
|
Nov 01
2024
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
50,716
-6.63%
|
$1,622,912
$32.15 P/Share
|
|
Nov 01
2024
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,716
+13.23%
|
$855,036
$21.09 P/Share
|
|
Nov 01
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
15,485
-17.27%
|
$495,520
$32.62 P/Share
|
|
Nov 01
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,485
+14.73%
|
$325,185
$21.1 P/Share
|
|
Oct 30
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,515
-5.74%
|
$144,480
$32.53 P/Share
|
|
Oct 30
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,515
+5.43%
|
$94,815
$21.1 P/Share
|
|
Oct 18
2024
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
63,539
-4.75%
|
$1,969,709
$31.83 P/Share
|
|
Oct 18
2024
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
63,539
+8.67%
|
$1,334,319
$21.1 P/Share
|
|
Oct 17
2024
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
3,103
-0.51%
|
$96,193
$31.12 P/Share
|
|
Oct 17
2024
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,103
+0.51%
|
$65,163
$21.1 P/Share
|
|
Oct 16
2024
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
24,992
-3.96%
|
$774,752
$31.14 P/Share
|
|
Oct 16
2024
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
24,992
+3.81%
|
$524,832
$21.1 P/Share
|
|
Oct 15
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
14,825
-8.26%
|
$444,750
$30.72 P/Share
|
|
Oct 15
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,825
+14.13%
|
$0
$0.62 P/Share
|
|
Oct 14
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
6,136
-7.64%
|
$184,080
$30.03 P/Share
|
|
Oct 14
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+5.86%
|
$0
$0.62 P/Share
|
|
Oct 14
2024
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
40,000
-15.02%
|
$1,200,000
$30.15 P/Share
|
|
Oct 14
2024
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+13.06%
|
$840,000
$21.09 P/Share
|
|
Oct 01
2024
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.23%
|
$280,000
$28.18 P/Share
|